207 related articles for article (PubMed ID: 35796863)
1. Efficacy and safety of chimeric antigen receptor T-cells treatment in central nervous system lymphoma: a PRISMA-compliant single-arm meta-analysis.
Lv L; Wu Y; Shi H; Sun X; Deng Z; Huo H; Li R; Liu Y
Cancer Immunol Immunother; 2023 Jan; 72(1):211-221. PubMed ID: 35796863
[TBL] [Abstract][Full Text] [Related]
2. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL.
Qi Y; Zhao M; Hu Y; Wang Y; Li P; Cao J; Shi M; Tan J; Zhang M; Xiao X; Xia J; Ma S; Qiao J; Yan Z; Li H; Pan B; Sang W; Li D; Li Z; Zhou J; Huang H; Liang A; Zheng J; Xu K
Blood; 2022 Jun; 139(23):3376-3386. PubMed ID: 35338773
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma.
Zhang H; Yan Z; Wang Y; Qi Y; Hu Y; Li P; Cao J; Zhang M; Xiao X; Shi M; Xia J; Ma S; Qiao J; Li H; Pan B; Qi K; Cheng H; Sun H; Zhu F; Sang W; Li D; Li Z; Zheng J; Zhao M; Liang A; Huang H; Xu K
Front Immunol; 2022; 13():965224. PubMed ID: 36059496
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Toxicity of CD19 Chimeric Antigen Receptor T Cell Therapy for Lymphoma in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis.
Yamshon S; Gribbin C; Chen Z; Demetres M; Pasciolla M; Alhomoud M; Martin P; Shore T
Transplant Cell Ther; 2024 Jan; 30(1):73.e1-73.e12. PubMed ID: 37279856
[TBL] [Abstract][Full Text] [Related]
6. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study.
Pan J; Tang K; Luo Y; Seery S; Tan Y; Deng B; Liu F; Xu X; Ling Z; Song W; Xu J; Duan J; Wang Z; Li C; Wang K; Zhang Y; Yu X; Zheng Q; Zhao L; Zhang J; Chang AH; Feng X
Lancet Oncol; 2023 Nov; 24(11):1229-1241. PubMed ID: 37863088
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Ibrutinib in Central Nervous System Lymphoma: A PRISMA-Compliant Single-Arm Meta-Analysis.
Lv L; Sun X; Wu Y; Cui Q; Chen Y; Liu Y
Front Oncol; 2021; 11():707285. PubMed ID: 34277452
[TBL] [Abstract][Full Text] [Related]
9. Sustained efficacy of chimeric antigen receptor T-cell therapy in central nervous system lymphoma: a systematic review and meta-analysis of individual data.
Zhou J; Wang Z; Wang H; Cao Y; Wang G
Front Pharmacol; 2023; 14():1331844. PubMed ID: 38328579
[No Abstract] [Full Text] [Related]
10. Humanized CD19-directed CAR-T Cell Therapy in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia With CNSL or Neurological Comorbidity.
Zhang N; Shao J; Li H; Zhu J; Xia M; Chen K; Jiang H
J Immunother; 2022 Nov-Dec 01; 45(9):396-406. PubMed ID: 36018262
[TBL] [Abstract][Full Text] [Related]
11. Adoptive Immunotherapy for B-cell Malignancies Using CD19- Targeted Chimeric Antigen Receptor T-Cells: A Systematic Review of Efficacy and Safety.
Hao L; Li T; Chang LJ; Chen X
Curr Med Chem; 2019; 26(17):3068-3079. PubMed ID: 28762313
[TBL] [Abstract][Full Text] [Related]
12. CD19 or CD20 CAR T Cell Therapy Demonstrates Durable Antitumor Efficacy in Patients with Central Nervous System Lymphoma.
Liu R; Cheng Q; Kang L; Wang E; Li Y; Zhang J; Xiao H; Zhang Y; Chu L; Chen X; Zhang C; Tan J; Xu N; Li M; Yu L; Li X
Hum Gene Ther; 2022 Mar; 33(5-6):318-329. PubMed ID: 35152726
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.
Anagnostou T; Riaz IB; Hashmi SK; Murad MH; Kenderian SS
Lancet Haematol; 2020 Nov; 7(11):e816-e826. PubMed ID: 33091355
[TBL] [Abstract][Full Text] [Related]
14. Toxicity and effectiveness of CD19 CAR T therapy in children with high-burden central nervous system refractory B-ALL.
Tan Y; Pan J; Deng B; Ling Z; Song W; Xu J; Duan J; Wang Z; Yu X; Chang AH; Feng X
Cancer Immunol Immunother; 2021 Jul; 70(7):1979-1993. PubMed ID: 33416942
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Dual-Targeting Chimeric Antigen Receptor-T Therapy for Relapsed or Refractory B Cell Lymphoid Malignancies: A Systematic Review and Meta-Analysis.
Yu M; Zhang Q; Kong F; Qi L; Pu Y; Qiu L; Wang J; Li F
Hum Gene Ther; 2023 Mar; 34(5-6):192-202. PubMed ID: 36734417
[TBL] [Abstract][Full Text] [Related]
16. Ray of dawn: Anti-PD-1 immunotherapy enhances the chimeric antigen receptor T-cell therapy in Lymphoma patients.
Zhou Y; Mu W; Wang C; Zhuo Z; Xin Y; Li H; Wang C
BMC Cancer; 2023 Oct; 23(1):1019. PubMed ID: 37872514
[TBL] [Abstract][Full Text] [Related]
17. Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma.
Wu J; Meng F; Cao Y; Zhang Y; Zhu X; Wang N; Wang J; Huang L; Zhou J; Xiao Y
Blood Cancer J; 2021 Jul; 11(7):131. PubMed ID: 34267187
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy and safety of CD19 chimeric antigen receptor T cells for the treatment of 22 patients with B-cell lymphoma].
Xiao X; Jiang YY; Cao YQ; Li Q; Jin X; Meng JX; Sui T; Li YM; Zhao MF
Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):276-280. PubMed ID: 31104437
[No Abstract] [Full Text] [Related]
19. Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study.
Epperla N; Feng L; Shah NN; Fitzgerald L; Shah H; Stephens DM; Lee CJ; Ollila T; Shouse G; Danilov AV; David KA; Torka P; Hashmi H; Hess B; Barta SK; Romancik JT; Cohen JB; Annunzio K; Kittai AS; Reneau J; Zurko J; Nizamuddin IA; Winter JN; Gordon LI; Ma S; Patel R; Nastoupil L; Ahmed S; Karmali R
J Hematol Oncol; 2023 Nov; 16(1):111. PubMed ID: 37946255
[TBL] [Abstract][Full Text] [Related]
20. A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells.
Fergusson NJ; Adeel K; Kekre N; Atkins H; Hay KA
Front Immunol; 2023; 14():1178403. PubMed ID: 37180149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]